Abstract
Inclusion bodies produced in Escherichia coli are composed of densely packed denatured protein molecules in the form of particles (1,2). In addition to the recombinant protein of interest, inclusion bodies contain small amounts of host protein, ribosomal components, and DNA/RNA fragments (3). It is advisable to purify the inclusion bodies from the cells to a high-degree purity before carrying out solubilization and purification. This will reduce the number of purification steps after solubilization and refolding, minimize the interference of other contaminating proteins during refolding, and result in a therapeutic protein free from other cellular contaminants, such as lipids, carbohydrate, and endotoxin (4). Isolation of inclusion bodies from E. coli occurs by cell lysis with high-pressure disruption using a French press or sonication step followed by centrifugation (5). Further purification can be achieved by washing with detergents and a low concentration of salt and/or urea (5,6). The presence of contaminants, along with the protein of interest, is mainly because of incomplete purification of the inclusion bodies following cell lysis. With proper centrifugation and washing processes, more than 95% pure inclusion bodies of recombinant proteins can be isolated from E. coli cells (7). As the inclusion bodies have a high density (approx 1.3 mg mL−1), these are easily separated by high-speed centrifugation after cell disruption (8). Centrifugal isolation, particularly sucrose gradient centrifugation, has been found to be the best method for isolating very pure inclusion bodies from E. coli cell lysate (9). Expression of recombinant human growth hormone (r-hGH) in E. coli will illustrate the methods used for isolation and purification of intact inclusion bodies. The purified inclusion bodies will then be used for solubilization and refolding to obtain bioactive protein.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mitraki, A., Fane, B., Haase-Pettingell, C., Sturtevant, J., and King, J. (1991) Global suppression of protein folding defects and inclusion body formation. Science 253, 54–58.
Carrio, M. M., Cubarsi, R., and Villaverde, A. (2000) Fine architecture of bacterial inclusion bodies. FEBS Lett. 471, 7–11.
Valax, P., and Georgiou, G. (1993) Molecular characterization of beta-lactamase inclusion bodies produced in Escherichia coli. 1. Composition. Biotechnol. Prog. 9, 539–547.
Clark, E. D. B. (1998) Refolding of recombinant proteins. Curr. Opin. Biotechnol. 9, 157–163.
Georgiou, G. and Valax, P. (1999) Isolating inclusion bodies from bacteria. Methods Enzymol. 309, 48–58.
Lilie, H., Schwarz, E., and Rudolph, R. (1998) Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol. 9, 497–501.
Khan, R. H., AppaRao, K. B. C., Eshwari, A. N. S., Totey, S. M., and Panda, A. K. (1998) Solubilization of recombinant ovine growth hormone with retention of native-like secondary structure and its refolding from the inclusion bodies of Escherichia coli. Biotechnol. Prog. 14, 722–728.
Taylor, G., Hoare, M., Gray, D. R., and Marston, F. A. O. (1986) Size and density of protein inclusion bodies. Biotechnology 4, 553–557.
Bowden, G. A., Paredes, A. M., and Georgiou, G. (1991) Structure and morphology of protein inclusion bodies in Escherichia coli. Biotechnology 9, 725–730.
Rudolph, R. and Lilie, H. (1996) In vitro folding of inclusion body proteins. FASEB J. 10, 49–56.
Misawa, S. and Kumagai, I. (1999) Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies. Biopolymers 51, 297–307.
Clark, E. D. (2001) Protein refolding for industrial processes. Curr. Opin. Biotechnol. 12, 202–207.
Creighton, T. E., Darby, N. J., and Kemmink, J. (1996) The roles of partly folded intermediates in protein folding. FASEB J. 10, 110–118.
Cardamone, M., Puri, N. K., and Brandon, M. R. (1995) Comparing the refolding and reoxidation of recombinant porcine growth hormone from a urea denatured state and from Escherichia coli inclusion bodies. Biochemistry 34, 5773–5794.
St John, R. J., Carpenter, J. F., Balny, C., and Randolph, T. W. (2001) High pressure refolding of recombinant human growth hormone from insoluble aggregates. Structural transformations, kinetic barriers, and energetics. J. Biol. Chem. 276, 46856–46863.
Patra, A. K., Mukhopadhyay, R., Mukhija, R., Krishnan, A., Garg, L. C., and Panda, A. K. (2000) Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr. Purif. 18, 182–192.
Patra, A. K., Gahlay, G. K., Reddy, B. V., Gupta, S. K., and Panda, A. K. (2000) Refolding, structural transition and spermatozoa-binding of recombinant bonnet monkey (Macaca radiata) zona pellucida glycoprotein-C expressed in Escherichia coli. Eur. J. Biochem. 267, 7075–7081.
Evangelista Dyr, J. and Suttnar, J. (1997) Separations used for the purification of recombinant proteins. J. Chromatogr. B, Biomed. Sci. Appl. 699, 383–401.
Amersham Pharmacia Biotech. Ion Exchange Chromatography Principles and Methods. Amersham Pharmacia Biotech, Uppsala, Sweden, 1999.
Ribela, M. T., Gout, P. W., and Bartolini, P. (2003) Synthesis and chromatographic purification of recombinant human pituitary hormones. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 790, 285–316.
Becker, G. W. and Hsiung, H. M. (1986) Expression, secretion and folding of human growth hormone in Escherichia coli. Purification and characterization. FEBS Lett. 204, 145–150.
Igout, A., Van Beeumen, J., Frankenne, F., Scippo, M. L., Devreese, B., and Hennen, G. (1993) Purification and biochemical characterization of recombinant human placental growth hormone produced in Escherichia coli. Biochem. J. 295, 719–724.
Speed, M. A., Wang, D. I., and King, J. (1996) Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nat. Biotechnol. 14, 1283–1287.
De Bernardez Clark, E., Schwarz, E., and Rudolph, R. (1999) Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol. 309, 217–236.
Tsumoto, K., Ejima, D., Kumagai, I., and Arakawa, T. (2003) Practical considerations in refolding proteins from inclusion bodies. Protein Expr. Purif. 28, 1–8.
Lindwall, G., Chau, M., Gardner, S. R., and Kohlstaedt, L. A. (2000) A sparse matrix approach to the solubilization of overexpressed proteins. Protein Eng. 13, 67–71.
Altamirano, M. M., Golbik, R., Zahn, R., Buckle, A. M., and Fersht, A. R. (1997) Refolding chromatography with immobilized mini-chaperones. Proc. Natl. Acad. Sci. USA 94, 3576–3578.
Vinogradov, A. A., Kudryashova, E. V., Levashov, A. V., and van Dongen, W. M. (2003) Solubilization and refolding of inclusion body proteins in reverse micelles. Anal. Biochem. 320, 234–238.
Batas, B., Schiraldi, C., and Chaudhuri, J. B. (1999) Inclusion body purification and protein refolding using microfiltration and size exclusion chromatography. J. Biotechnol. 68, 149–158.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Singh, S.M., Eshwari, A.N.S., Garg, L.C., Panda, A.K. (2005). Isolation, Solubilization, Refolding, and Chromatographic Purification of Human Growth Hormone from Inclusion Bodies of Escherichia coli Cells. In: Smales, C.M., James, D.C. (eds) Therapeutic Proteins. Methods in Molecular Biology™, vol 308. Humana Press. https://doi.org/10.1385/1-59259-922-2:163
Download citation
DOI: https://doi.org/10.1385/1-59259-922-2:163
Publisher Name: Humana Press
Print ISBN: 978-1-58829-390-9
Online ISBN: 978-1-59259-922-6
eBook Packages: Springer Protocols